| Title | Statin Use and the Incidence of Advanced Age-Related Macular Degeneration in the Complications of Age-Related Macular Degeneration Prevention Trial. | | Author(s) | Maguire MG, Ying GS, McCannel CA, Liu C, Dai Y, Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group | | Institution | Department of Ophthalmology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. | | Source | Ophthalmology 2009 Oct 21. | | Abstract | OBJECTIVE: To evaluate the impact of statin use on the incidence of advanced age-related macular degeneration (AMD) and its components, choroidal neovascularization (CNV) and geographic atrophy (GA), among patients with bilateral large drusen.
DESIGN: Cohort study within a multicenter, randomized, clinical trial.
PARTICIPANTS: Patients enrolled in the Complications of Age-related Macular Degeneration Prevention Trial (CAPT).
METHODS: Eligibility criteria for the clinical trial required that participants have >/=10 large (>125 mum) drusen and visual acuity >/=20/40 in each eye. Patients scheduled for their final CAPT visit after May 2005 were interviewed on their history of use of cholesterol-lowering medications, including statins. Trained readers identified CNV and end point GA (>1 Macular Photocoagulation Study disc area of GA) based on review of fluorescein angiograms and fundus photographs taken at annual follow-up visits and when patients reported symptoms. The risk ratio for participants developing CNV or developing GA associated with statin use was estimated with time-dependent Cox proportional hazards models.
MAIN OUTCOME MEASURES: Development of advanced AMD, CNV, and end point GA.
RESULTS: Among 764 patients eligible for the interview, 744 (97.4%) patients completed the interview on medication use. Statin use was reported by 296 (39.8%) of those interviewed, with the majority, 187 (63.2%) of the 296, beginning use after enrollment in CAPT. Among 744 patients, advanced AMD developed in 332 (22.5%) eyes of 242 (32.5%) patients, CNV in 222 (15%) eyes of 176 (23.7%) patients, and GA in 114 (7.7%) eyes of 80 (10.8%) patients. With adjustment for other risk factors, the estimated risk ratio for eyes (95% confidence interval) associated with statin use was 1.15 (0.87-1.52) for advanced AMD, 1.35 (0.99-1.83) for CNV, and 0.80 (0.46-1.39) for GA.
CONCLUSIONS: The CAPT data are not consistent with a strong protective effect (risk ratio, </=0.85) of statins on the development of advanced AMD among patients with bilateral large drusen. FINANCIAL DISCLOSURES: The authors have no proprietary or commercial interest in any of the materials discussed in this article. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19850347 |
|
